1. Introduction
ccording to World Health Organisation (WHO), Pharmacovigilance (PV) as the pharmacological science and activities relating to the monitoring, detection, assessment, understanding, and prevention of adverse drug reactions (ADRs), or any long-term and short-term medicine-related problems (Figure 1&2). Variety of ADRs associated with medication prompted the event of the science of PV [1][2][3][4] . This prompted WHO for a systematic study of ADR of medicine, that is that the starting of PV. Thenceforth variety of ADRs was detected, a number of that square measure shows in (Table 1). ADR is taken into account to be the 6 th leading reason behind death. India, with a current population of 1.27 billion, is that the 4th largest producers of prescription drugs within the world with quite 6000 licensed makers and over 60000 branded formulations within the market. In the United States of America, ADRs contribute 3-7% of hospital admissions. In England, 1% chronicles of the entire hospital admissions were due to ADRs throughout the year 1999-2008. ADRs square measure common in the Australian healthcare system additionally and that they contribute to a 1% of hospital admissions [5,6] . The percentage of hospital admissions due to ADRs in bound countries is 100% or additional.
Drug attributed deaths square measure calculable to be 0.19% altogether medical inpatients. About 0.40% of ADRs known were directly joined to high costs. ADRs not solely increase the mortality and morbidity; however, additionally multiply the health care value [7] . The PV effort within India is coordinated bythe Indian Pharmacopoeia Commission (IPC) and conducted by the Central Drugs Standard Control Organization (CDSCO). The most responsibility of the IPC is to keep up and develop the PV database consisting of all suspected ADR to medicines observed. IPC is functioning as a National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI). NCC is working underneath the direction of a committee that recommends procedures and guidelines for regulatory interventions [8] .The main responsibility of NCC is to watch all the ADR of medicines being observed within the Indian population and to develop and maintain its PV information. The aim of the commission that acts just like the NCC for PvPI is for the safety of the patient, and the population with relevancy use of the drug. The Commission has become operational from 1 st January 2009 an associate autonomous body, absolutely supported by the central government with specific fund allocations under the administrative control of the Ministry of Health and Family Welfare [9] . The Secretary, Ministry of Health and Family Welfare, is the Chairperson and therefore the Chairman-Scientific Body is that the Co-Chairman of the Commission. The Secretary-cum Scientific Director is that the Chief Scientific and Executive officer of the Commission. The CDSCO, Directorate General of Health Services underneath the aegis of Ministry of Health & Family Welfare, Government of India unitedly with IPC, Ghaziabad is initiating a nation-wide PV program for shielding the health of the patients by reassuring drug safety. The program shall be coordinated by the IPC, as an NCC. The center can operate underneath the superintendence of a steering committee. The PvPI was initiated by the government of India on 14 th July 2010 with the All India Institute of Medical Sciences (AIIMS), New Delhi as the NCC for monitoring ADRs in the country for safeguarding public health. Within the year 2010, 22 ADR monitoring center, as well as AIIMS, came upon underneath this program [10][11][12][13] . To confirm the implementation of this program in an exceedingly method, the NCC was shifted from the AIIMS to the IPC, Ghaziabad, Uttar Pradesh on 15th April 2011 (Figure 3). The concept of PV is not new, because the time of Charak Samhita in 700 BC had cautioned that properly understood however improperly administered drug is Vagueness poison and Vagbhatta-a physician represented adverse events, reason, delayed ADRs to Ayurvedic Drugs' around 500 AD. After that, many reports of ADRs from India area unit found within the history of modern medicine, but there was no systematic effort of ADR monitoring since the primary try was created in 1989 [15,16] .
2. III. Scope of the Pharmacovigilance Programme of India
Before registration and selling of drugs within the country, its safety and efficaciousness expertise area unit primarily based totally on the employment of the drugs in clinical trials. These trials in the notice common ADR. Some vital reactions, like those, that take a protracted time to develop, or those, that occur seldom, might not be detected in clinical trials. Additionally, the controlled conditions beneath that medicines area unit utilized in clinical trials don't essentially replicate the method they will be utilized in observe. For a drug to be thought-about safe, its expected advantages ought to be more than any associated risks of harmful reactions. So, to achieve a comprehensive safety profile of drugs, a continuous post-marketing monitoring system, i.e. PV is crucial. To monitor the security of drugs, information from several sources is employed for PV [17] . These embrace spontaneous ADRs coverage mechanism; medical literature published worldwide; action taken by regulative authorities in alternative countries. Since there exist substantial social and economic consequences of ADRs and therefore the positive benefit/cost magnitude relation of implementing applicable risk management -there may be a have to be compelled to interact health care professionals and therefore the public at massive, during a well-structured program to make synergies for watching ADRs within the country. The PvPI aims is to collate data, method and analyze it and use the inferences to advocate regulative interventions, besides human action risks to health care professionals and therefore, the public [18 ].
IV.
3. Management of the Pharmacovigilance Programme of India
This is headed by the Secretary cum scientific Director: Dr. Gyanendra Nath Singh, who is working with the help of Advisor and National Scientific Coordinator supported by the several committees like-Steering Committee, Working Group, Quality Review Panel, Core Training Panel, etc. involving experts from all over the country.Current Status of NCC-PvPI Presently the PvPI program has more than 200 Adverse Drug Monitoring Centres (AMCs) involving all states and Union Territories through-out India [19] .
V.
4. Reporting of Adverse Drug Reactions
Suspected ADR reporting forms for health care professionals (Figure 4) and consumers (Figure 5) a unit available on the website of IPC to report ADR. To get rid of barrier in ADR reporting, the consumer reporting form is available in 10 vernacular languages (Hindi, Tamil, Telugu, Kannada, Bengali, Gujarati, Assamese, Marathi, Oriya, and Malayalam). ADRs will be conjointly reportable via PvPI helpline number (18001803024) on week days from 9:00 am to 5:30 pm. The mobile Android application for ADR reporting has conjointly been created available to the general public [20] .
5. VI.
6. World Health Organization-Uppsala Monitoring Centre & India
The WHO Program for International Drug Monitoring provides a forum for WHO member states that has India to collaborate within the monitoring of drug safety. At intervals the Program, individual case reports of suspected ADRs are collected and keep in an exceedingly common information, presently containing over 3.7 million case reports. Since 1978, the Uppsala Monitoring Centre (UMC) in Sweden has dispensed the Program. The UMC is accountable for the gathering of knowledge concerning ADRs from around the world, particularly from countries that are members of the WHO together with India. Member countries send their reports to the UMC wherever they are processed, evaluated, and entered into the WHO International information. When there are several reports of adverse reactions to a particular drug, this process may lead to the detection of a signal-an alert about a possible hazard communicated to member countries. This happens solely once elaborated analysis and expert review. These ADR reports are assessed regionally and will cause the action at intervals in the country. Through membership of the WHO International Drug Monitoring Program, a rustic will recognize if similar reports are being created elsewhere. India is a country with a large patient pool and healthcare professionals, yet ADR reporting is in its infancy (Table 2) [21][22][23] .
7. VII.
8. Aim of the Pharmacovigilance Programme of India
Pharmacovigilance has specific aims as follows:
1. Improve patient care and safety in about the use of medicines and all medical and paramedical interventions. 2. Improve public health and safety in about the use of medicines. 3. Contribute to the assessment of benefit, harm, effectiveness, and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use.
9. Promote understanding, education, and clinical
training in PV and its effective communication to the public [24] . IX.
10. Conclusion
The adverse drug reaction observation and reporting programs or pharmacovigilance program of India is aiming to identify the risks related to the utilization of the drugs. The current analysis has disclosed opportunities or interventions particularly or avertible adverse events, which arecan to facilitate in promoting safer drug use, data to the health care professionals. Improve the standard of patient care and educate to extend awareness. Therefore, currently, this point has returned to aware the general public too for the reporting the adverse drug reaction to the nearest hospital or ADR monitoring center or the health care professionals. They will directly report the adverse drug reaction through the government. Toll-free number 18001803024, adverse drug reaction application, email, and alternative methodology like social media.
11. B
Pharmacovigilance Programme of India: A Review 4. To generate the evidence-based information on the safety of medicines. 5. To support regulatory agencies in the decisionmaking process on the use of medications. 6. To communicate the safety information on the use of medicines to various stakeholders to minimize the risk. 7. To emerge as a national center of excellence for PV activities. 8. To collaborate with other national centers for the exchange of information and data management. 9. To provide training and consultancy support to other national PV centers located across the globe [25,26] .
| Sr. No. | Drug | Year | Serious & unexpected adverse event |
| Chloroform (Anaesthetic) | 1848 | Episode of ventricular fibrillation & death | |
| Sulphanilamide (Elixir) | 1937 | Death | |
| Thalidomide | 1961 | Amelia, phocomelia &dysmelia | |
| Clioquinol | 1970 | Subacute nephropathy | |
| Practolol | 1975 | Sclerosing peritonitis | |
| Benoxaprofen | 1982 | Nephrotoxicity&cholestatic jaundice | |
| Terfenadine | 1997 | Torsade de pointes | |
| Rofecoxib | 2004 | Cardiovascular effects | |
| Veralipride | 2007 | Anxiety, depression & movement disorders | |
| Centre | Role |
| Collection of ADR reports, perform follow up with the | |
| complainant to check completeness as per standard | |
| operating procedure (SOPs), data entry into Vigiflow, | |
| ADR monitoring centre | reporting to PvPI-NCC through Vigiflow with the source |
| data (original) attached with each ADR caseTraining/ | |
| sensitization/ feedback to physicians through newsletters | |
| circulated by the PvPI-NCC. | |
| PvPI AMC other than medical colleges [Corporate | |
| hospitals, autonomous institutes, Pharmaceutical | |
| industry and public health Programmers] | |
| Preparation of SOPs, guidance documents & training | |
| manuals, | |
| Pharmacovigilance programme of India, National | data collation, Cross-check completeness, Causality |
| coordinating centre, Indian pharmacopoeia | Assessment etc as per SOPs, conduct Training |
| commission(Ghaziabad) | workshops of all enrolled centres, publication of |
| medicines safety newsletter, reporting to CDSCO-HQ, | |
| Analysis of the Performance measurement system, | |
| Periodic safety update report, Adverse event following | |
| immunization data received from CDSCO-HQ. | |
| Provide procurement, financial and administrative support | |
| Zonal/Sub-zonal CDSCO Offices | to ADR monitoring centres, report to CDSCO-HQ. |
| Take appropriate regulatory decision & actions on the | |
| basis of recommendations of PvPI NCC at IPC, | |
| Central drugs standard control organization- | propagation of medicine safety related decisions to |
| Headquarter (New Delhi) | stakeholders, collaboration with WHO-UMC, provide for |
| budgetary provisions &administrative support to run PvPI. |